Immune Response to the Introduction of Fibrillogenic β2-Microglobulin Protein Conjugated with Different Types of Polymer Particles

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The effect of the composition and size of polymeric particles on the immunogenicity of the fibrillogenic β2-microglobulin protein immobilized on their surface was studied. For this purpose, nanoparticles (NP) based on a copolymer of L-glutamic acid and L-phenylalanine (P(Glu-co-Phe)) and a block copolymer of poly(ethylene glycol) with poly(lactic acid) (PEG-b-PLA) as well as microparticles (MP) based on poly(lactic acid) (PLA) were selected. α-L-amino acid copolymer-based nanoparticles were prepared by gradient phase inversion, and PEG-b-PLA-based nanoparticles by nanoprecipitation. Double emulsion method was used to form polymeric microparticles based on PLA. Recombinant chimeric model protein beta-2-microglobulin-green fluorescent protein (β2M-sfGFP) was used to covalently modify all types of polymeric particles followed by immunization of four groups of laboratory animals equal in number. An enzyme immunoassay method was used to evaluate the humoral immune response. In three experimental groups, mice were immunized using poly(amino acid)-based nanoparticles (NP-PAA) and PEG-b-PMC (NP-PLA) as well as PLA microparticles containing immobilized β2M-sfGFP on the surface. The control group was immunized using a physical mixture of PEG-b-PLA nanoparticles and free β2M-sfGFP. The highest level of antibodies to sfGFP in blood serum was found when mice were immunized with a mixture of protein and nanoparticles. When mice were immunized with β2M-sfGFP-modified nanoparticles, the amount of antibodies to sfGFP was statistically significantly lower (p<0.001) compared to the control group. However, the groups immunized with nanoparticles of similar size but different composition conjugated to the model proteins did not differ significantly among themselves. It was also found that the size of the particles affects the immunogenicity of the associated protein. A similar pattern of relative antibody content in the sera of mice was maintained at all steps of immunization.

Sobre autores

R. Sakhabeev

St. Petersburg Institute of Technology (Technical University); Institute of Experimental Medicine

Autor responsável pela correspondência
Email: helm505@mail.ru
Russia, St. Petersburg; Russia, St. Petersburg

D. Polyakov

Institute of Experimental Medicine

Email: helm505@mail.ru
Russia, St. Petersburg

E. Sinitsyna

Institute of Macromolecular Compounds, Russian Academy of Sciences

Email: helm505@mail.ru
Russia, St. Petersburg

E. Korzhikova-Vlakh

Institute of Macromolecular Compounds, Russian Academy of Sciences

Email: helm505@mail.ru
Russia, St. Petersburg

V. Korzhikov-Vlakh

Institute of Macromolecular Compounds, Russian Academy of Sciences; Saint-Petersburg State University

Email: helm505@mail.ru
Russia, St. Petersburg; Russia, St. Petersburg

M. Shavlovsky

Institute of Experimental Medicine

Email: helm505@mail.ru
Russia, St. Petersburg

Bibliografia

  1. Rawal S, Patel MM (2019) Threatening cancer with nanoparticle aided combination oncotherapy. J Control Release 301: 76–109. https://doi.org/10.1016/j.jconrel.2019.03.015
  2. Kumar B, Jalodia K, Kumar P, Gautam HK (2017) Recent advances in nanoparticle-mediated drug delivery. J Drug Deliv Sci Technol 41: 260–268. https://doi.org/10.1016/j.jddst.2017.07.019
  3. Polyakov D, Sinitsyna E, Grudinina N, Antipchik M, Sakhabeev R, Korzhikov-Vlakh V, Shavlovsky M, Korzhikova-Vlakh E, Tennikova T (2021) Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus. Pharmaceutics 13: 672. https://doi.org/10.3390/pharmaceutics13050672
  4. Pati R, Shevtsov M, Sonawane A (2018) Nanoparticle Vaccines Against Infectious Diseases. Front Immunol 9: 02224. https://doi.org/10.3389/fimmu.2018.02224
  5. Tewabe A, Abate A, Tamrie M, Seyfu A, Abdela Siraj E (2021) Targeted Drug Delivery — From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives. J Multidiscip Health14: 1711–1724. https://doi.org/10.2147/JMDH.S313968
  6. Oyewumi MO, Kumar A, Cui Z (2010) Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 9: 1095–1107. https://doi.org/10.1586/erv.10.89
  7. Ben-Akiva E, Est Witte S, Meyer RA, Rhodes KR, Green JJ (2019) Polymeric micro- and nanoparticles for immune modulation. Biomater Sci 7: 14–30. https://doi.org/10.1039/C8BM01285G
  8. Marin E, Briceno ML, Caballero-George C (2013) Critical evaluation of biodegradable polymers used in nanodrugs. Int J Nanomedicine 8: 3071–3091. https://doi.org/10.2147/IJN.S47186
  9. Elmowafy EM, Tiboni M, Soliman ME (2019) Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)/poly(lactic-co-glycolic acid) micro and nanoparticles. J Pharm Invest 494 (49): 347–380. https://doi.org/10.1007/S40005-019-00439-X
  10. Iudin D, Zashikhina N, Demyanova E, Korzhikov-Vlakh V, Shcherbakova E, Boroznjak R, Tarasenko I, Zakharova N, Lavrentieva A, Skorik Y, Korzhikova-Vlakh E (2020) Polypeptide self-assembled nanoparticles as delivery systems for polymyxins B and E. Pharmaceutics 12: 868. https://doi.org/10.3390/pharmaceutics12090868
  11. Boddu SHS, Bhagav P, Karla PK, Jacob S, Adatiya MD, Dhameliya TM, Ranch KM, Tiwari AK (2021) Polyamide/Poly(Amino Acid) Polymers for Drug Delivery. J Funct Biomater 12: 58. https://doi.org/10.3390/jfb12040058
  12. Richard A, Margaritis A (2001) Poly(Glutamic Acid) for Biomedical Applications. Crit Rev Biotechnol 21: 219–232. https://doi.org/10.1080/07388550108984171
  13. Zhang Y, Song W, Lu Y, Xu Y, Wang C, Yu DG, Kim I (2022) Recent Advances in Poly(α-L-glutamic acid)-Based Nanomaterials for Drug Delivery. Biomolecules 12: 636. https://doi.org/10.3390/biom12050636
  14. Singer JW (2005) Paclitaxel poliglumex (XYOTAXTM, CT-2103): A macromolecular taxane. J Control Release 109: 120–126. https://doi.org/10.1016/j.jconrel.2005.09.033
  15. Vonarbourg A, Passirani C, Saulnier P, Benoit JP (2006) Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 27: 4356–4373. https://doi.org/10.1016/j.biomaterials.2006.03.039
  16. He C, Hu Y, Yin L, Tang C, Yin C (2010) Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31: 3657–3666. https://doi.org/10.1016/j.biomaterials.2010.01.065
  17. Solovyov K V., Polyakov DS, Grudinina NA, Egorov VV, Morozova IV, Aleynikova TD, Shavlovsky MM (2011) Expression in E. coli and purification of the fibrillogenic fusion proteins ttr-sfgfp and β2M-sfGFP. Prep Biochem Biotechnol 41: 337–349. https://doi.org/10.1080/10826068.2010.548433
  18. Zashikhina N, Sharoyko V, Antipchik M, Tarasenko I, Anufrikov Y, Lavrentieva A, Tennikova T, Korzhikova-Vlakh E (2019) Novel Formulations of C-Peptide with Long-Acting Therapeutic Potential for Treatment of Diabetic Complications. Pharmaceutics 11: 27. https://doi.org/10.3390/pharmaceutics11010027
  19. Sinitsyna E, Bagaeva I, Gandalipov E, Fedotova E, Korzhikov-Vlakh V, Tennikova T, Korzhikova-Vlakh E (2022) Nanomedicines Bearing an Alkylating Cytostatic Drug from the Group of 1,3,5-Triazine Derivatives: Development and Characterization. Pharmaceutics 14: 2506. https://doi.org/10.3390/pharmaceutics14112506
  20. Korzhikov V, Averianov I, Litvinchuk E, Tennikova TB (2016) Polyester-based microparticles of different hydrophobicity: the patterns of lipophilic drug entrapment and release. J Microencapsul 33: 199–208. https://doi.org/10.3109/02652048.2016.1144818
  21. Korzhikov-Vlakh V, Averianov I, Sinitsyna E, Nashchekina Y, Polyakov D, Guryanov I, Lavrentieva A, Raddatz L, Korzhikova-Vlakh E, Scheper T, Tennikova T (2018) Novel Pathway for Efficient Covalent Modification of Polyester Materials of Different Design to Prepare Biomimetic Surfaces. Polymers 10: 1299. https://doi.org/10.3390/polym10121299
  22. Polyakov DS, Antimonova OI, Sakhabeev RG, Grudinina NA, Khodova AE, Sinitsyna ES, Korzhikov-Vlakh VA, Tennikova TB, Shavlovsky M (2017) Poly(lactic acid) nanoparticles influence on immunogenicity of the protein bound with them. Russ J Infect Immun 7: 123–129. https://doi.org/10.15789/2220-7619-2017-2-123-129
  23. Joshi VB, Geary SM, Salem AK (2013) Biodegradable Particles as Vaccine Delivery Systems: Size Matters. AAPS J 15: 85–94 . https://doi.org/10.1208/s12248-012-9418-6
  24. Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IFC, Plebanski M (2004) Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors. J Immunol 173: 3148–3154. https://doi.org/10.4049/jimmunol.173.5.3148

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2.

Baixar (36KB)
Metadados
3.

Baixar (58KB)
Metadados

Declaração de direitos autorais © Р.Г. Сахабеев, Д.С. Поляков, Е.С. Синицына, Е.Г. Коржикова-Влах, В.А. Коржиков-Влах, М.М. Шавловский, 2023

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies